COMP <GO>
IRLA vs AGEN // EV/EBITDA & P/E VALUATION
IRulya Therapeutics Inc. (NASDAQ) VS. Agenus Inc. (NASDAQ) • 15-METRIC TALLY: IRLA 3
— AGEN 1
■ METRIC PARITY
LAST: $31.62 (-4.05%) • MKT CAP: $342.8M
valuation
—
LAST: $7.09 (-0.56%) • MKT CAP: $320.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRLA VS. AGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRLA | AGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.19% | -24.11% | +11.92 | IRLA | /fcf-yield <GO> |
| Operating Margin | — | -17.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -2.70% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 10.40% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | AGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 46.7 | +5.81 | IRLA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $342.8M | $320.2M | $22.6M | IRLA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRLA REV | AGEN REV | IRLA GROSS % | AGEN GROSS % | IRLA FCF | AGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $114.2M | — | 98.0% | -$41.8M | -$77.2M |
| FY 2024 | $0 | $103.5M | — | 98.0% | -$32.2M | -$158.9M |
| FY 2023 | $0 | $156.3M | — | — | -$18.3M | -$224.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRLA // BETA —
AGEN // BETA —